Amicus Therapeutics Inc (FOLD)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

3675 MARKET STREET PHILADELPHIA, PA 19104

Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule, orally-administered drugs, known as pharmacological chaperones, for the treatment of a range of human genetic diseases. The pharmacological chaperone technology involves the use of small molecules to restore biological activity in cells by binding to a misfolded protein caused by a genetic mutation. The company is targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Its lead compound includes Amigal, which is in Phase II clinical trials is used for the treatment of Fabry disease that causes kidney failure, cardiac abnormalities, and neurological complications. The company is also developing AT2101 for the treatment of Gaucher disease, which causes an enlarged liver and spleen, low levels of red blood cells and platelets, bone pain, and fractures; and AT2220 for the treatment of Pompe disease, which causes muscle weakness primarily affecting breathing, mobility, and heart function. The company has a strategic collaboration with Shire Human Genetic Therapies, Inc. to jointly develop pharmacological chaperone compounds for lysosomal storage disorders.

Data as of 2021-04-11 06:43:18 -0400
Market Cap2.429 Billion Shares Outstanding264.316 Million Avg 30-day Volume3.172 Million
P/E Ratio-8.77387 Dividend Yield EPS-1.07
Price/Sales9.31 Debt to Equity3.1 EBITDA-235.008 Million
Price to Book Value8.48 Forward PE-10.74 Enterprise Value2.335 Billion
Total Cash483.269 Million Current Debt129.676 Million Gross Profit229.842 Million
BETA1.11293 52-week High/Low25.39 / 8.83 Next Earnings Date2021-05-06 Price to Cash FLow (P/CF) -9999999.0
Data provided by IEX Cloud
View SEC Filings from FOLD instead.
Q4 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 6 6 0.0% 6 (0.36%) 6 (0.37%) 0.0%
Funds Holding: 268 248 8.06% 90 (5.41%) 88 (5.48%) 2.27%
13F shares: 278.931 Million 274.227 Million 1.72% 138.55 Million 134.959 Million 2.66%
% Ownership 53.1684 51.7901 2.66%
New Positions: 49 44 11.36% 13 18 -27.78%
Increased Positions 88 76 15.79% 25 31 -19.35%
Closed Positions 27 19 42.11% 11 7 57.14%
Reduced Positions 96 93 3.23% 40 34 17.65%
Total Calls 3.603 Million 2.617 Million 37.64% 1.425 Million 977 Thousand 45.84%
Total Puts 3.715 Million 999.412 Thousand 271.74% 2.225 Million 478 Thousand 365.42%
PUT/CALL Ratio 1.03 0.38 171.05% 1.56 0.49 218.37%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding FOLD (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding FOLD BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

3 Thousand total shares from 2 transactions

Open Market Sells (S)

95.4 Thousand total shares from 8 transactions

Exercise Derivative Conversion (M)

81.7 Thousand total shares from 5 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

CROWLEY JOHN F CHAIRMAN & CEO

  • Officer
  • Director
964,808 2021-04-06 23

CAMPBELL BRADLEY L CHIEF OPERATING OFFICER

  • Officer
  • Director
412,022 2021-04-06 17

QUIMI DAPHNE CHIEF FINANCIAL OFFICER

  • Officer
290,629 2021-04-06 9

DO HUNG CHIEF SCIENCE OFFICER

  • Officer
448,617 2021-04-06 6

ROSENBERG ELLEN CHIEF LEGAL OFFICER

  • Officer
256,206 2021-04-06 5

CLARK DAVID MICHAEL CHIEF PEOPLE OFFICER

  • Officer
174,389 2021-04-06 3

WHITMAN BURKE W

  • Director
44,467 2021-04-01 12

PROUT SAMANTHA PRINCIPAL ACCOUNTING OFFICER

  • Officer
26,255 2021-01-02 6

KELLY MICHAEL AARON

  • Director
8,837 2020-12-01 2

BARTH JAY CHIEF MEDICAL OFFICER

  • Officer
163,224 2020-09-30 7

MCGLYNN MARGARET G

  • Director
27,919 2020-06-04 1

RAAB MICHAEL

  • Director
21,000 2020-06-04 2

SBLENDORIO GLENN

  • Director
33,933 2020-06-04 1

LOVE TED W

  • Director
131,000 2020-06-04 1

ESSNER ROBERT

  • Director
21,000 2020-06-04 1

WHEELER CRAIG A

  • Director
21,000 2020-06-04 1

BLEIL LYNN DORSEY

  • Director
21,705 2020-06-04 1

PERCEPTIVE ADVISORS LLC

PERCEPTIVE LIFE SCIENCES MASTER FUND LTD

EDELMAN JOSEPH

  • 10% Owner
20,724,424 2019-02-12 0

BAIRD WILLIAM D III CHIEF FINANCIAL OFFICER

  • Officer
117,622 2018-10-15 0

ANDREWS KURT J. SVP, HUMAN RESOURCES

  • Officer
35,469 2018-07-02 0

HAYDEN DONALD J JR

  • Director
8,895 2018-06-07 0

BARER SOL J

  • Director
0 2016-06-09 0

REDMILE GROUP, LLC

GREEN JEREMY

  • 10% Owner
12,890,146 2016-06-03 0

PEIST KENNETH VP, LEGAL & IP

  • Officer
18,874 2016-01-04 0

VALENZANO KEN SVP, PHARMACOLOGY & BIOLOGY

  • Officer
27,687 2015-07-13 0

DOSHI DIPAL SVP STRATEGY & BUS DEV

  • Officer
1,706 2015-07-07 0

GERSHKOWITZ JAYNE SVP, CHIEF PATIENT ADVOCATE

  • Officer
5,693 2015-07-01 0

CASTELLI JEFF SVP, PROGRAM MANAGEMENT

  • Officer
25,000 2015-06-22 0

DILONE ENRIQUE SVP, TECHNICAL OPERATIONS

  • Officer
30,688 2015-06-19 0

YU JULIE VP CLINICAL OPS & DATA MGMT

  • Officer
0 2015-06-15 0

KIRK JOHN VP, REGULATORY AFFAIRS

  • Officer
0 2015-06-01 0

BALDRY MARK VP GLOBAL MARKETING

  • Officer
25,000 2015-06-01 0

DAVID ALLSOP SVP INTERNATIONAL

  • Officer
0 2015-04-27 0

GLAXOSMITHKLINE PLC

  • FORMER 10% OWNER (1)
No longer subject to file 2014-10-27 0

BARRETT M JAMES

  • Director
  • 10% Owner
0 2014-06-12 0

TOPPER JAMES N

  • Director
0 2014-06-12 0

LOCKHART DAVID J CHIEF SCIENTIFIC OFFICER

  • Officer
0 2013-06-18 0

WINTERBOTTOM JOAN SVP, HUMAN RESOURCES

  • Officer
0 2013-06-18 0

MACALUSO PETER M VP & CORPORATE COUNSEL

  • Officer
0 2013-06-18 0

WINKLER ROBERT E VP, CLIN RESEARCH & OPERATIONS

  • Officer
0 2012-06-04 0

BOUDES POL F CHIEF MEDICAL OFFICER

  • Officer
0 2012-06-04 0

GILMORE GEOFFREY SVP & GENERAL COUNSEL

  • Officer
0 2012-03-12 0

BARRIS PETER J

  • 10% Owner
5,650,340 2012-03-07 0

KRAMLICH C RICHARD

  • 10% Owner
5,650,340 2012-03-07 0

NEWHALL CHARLES W III

  • 10% Owner
5,650,340 2012-03-07 0

PERRY MARK W

  • 10% Owner
5,650,340 2012-03-07 0

NEW ENTERPRISE ASSOCIATES 11 LP

NEA PARTNERS 11 LP

NEA 11 GP, LLC

BASKETT FOREST

DRANT RYAN D

KOLLURI KRISHNA KITTU

SANDELL SCOTT D

  • 10% Owner
4,584,311 2012-03-07 0

SCHAEFFER ORLOV S NICOLE SVP, HR & LEADERSHIP DEVT

  • Officer
0 2012-02-15 0

BARKAS ALEXANDER E

  • Director
0 2011-05-24 0

PATTERSON MATTHEW R ACTING CEO & PRESIDENT

  • Officer
106,547 2011-04-18 0

NEFF P SHERRILL

  • Director
0 2010-06-15 0

JOHN MCADAM M VP, FINANCE & ACCOUNTING

  • Officer
0 2010-06-15 0

DENTZER JAMES E CHIEF FINANCIAL OFFICER

  • Officer
32,075 2009-10-01 0

PALLING DAVID SR VP, TECHNICAL OPERATIONS

  • Officer
34,040 2009-06-26 0

BLOCH STEPHEN M

  • Director
1,714,090 2009-02-11 0

LICHOLAI GREGORY P VP, MEDICAL AFFAIRS

  • Officer
0 2009-02-03 0

SHENKER ANDREW VP, CLINICAL RESEARCH

  • Officer
0 2009-02-03 0

WEINHOFF GREGORY M

  • Director
2,058,555 2008-08-14 0

FHM IV LP

FRAZIER HEALTHCARE V, LP

FHM V, LP

FHM V, LLC

FRAZIER HEALTHCARE IV LP

FRAZIER AFFILIATES IV LP

  • 10% Owner
915,924 2008-03-06 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

CLARK DAVID MICHAEL - Officer CHIEF PEOPLE OFFICER

2021-04-08 20:06:06 -0400 2021-04-06 A 16,883 a 174,389 direct 1.0881 8.161 12.4048 5 0.0 1

ROSENBERG ELLEN - Officer CHIEF LEGAL OFFICER

2021-04-08 20:00:18 -0400 2021-04-06 A 20,501 a 241,206 direct 1.0881 8.161 12.4048 5 0.0 1

CAMPBELL BRADLEY L - Director - Officer CHIEF OPERATING OFFICER

2021-04-08 20:03:06 -0400 2021-04-06 A 33,165 a 412,022 direct 1.0881 8.161 12.4048 5 0.0 1

QUIMI DAPHNE - Officer CHIEF FINANCIAL OFFICER

2021-04-08 20:01:37 -0400 2021-04-06 A 19,295 a 290,629 direct 1.0881 8.161 12.4048 5 0.0 1

DO HUNG - Officer CHIEF SCIENCE OFFICER

2021-04-08 20:05:06 -0400 2021-04-06 A 20,501 a 448,617 direct 1.0881 8.161 12.4048 5 0.0 1

CROWLEY JOHN F - Director - Officer CHAIRMAN & CEO

2021-04-08 20:04:03 -0400 2021-04-06 A 78,389 a 899,913 direct 1.0881 8.161 12.4048 5 0.0 1

CAMPBELL BRADLEY L - Director - Officer CHIEF OPERATING OFFICER

2021-04-05 18:19:13 -0400 2021-04-01 S 10,514 $10.03 d 378,857 direct yes -1.9874 -2.6151 0.0 1 -3.8703 4

WHITMAN BURKE W - Director

2021-04-05 18:15:17 -0400 2021-04-01 P 1,500 $10.00 a 44,467 direct yes -1.9874 -2.6151 0.0 1 -3.8703 4

CAMPBELL BRADLEY L - Director - Officer CHIEF OPERATING OFFICER

2021-04-05 18:19:13 -0400 2021-04-01 M 10,514 $6.45 a 389,371 direct -1.9874 -2.6151 0.0 1 -3.8703 4

CAMPBELL BRADLEY L - Director - Officer CHIEF OPERATING OFFICER

2021-04-05 18:19:13 -0400 2021-04-01 M 10,514 d 17,137 direct

CROWLEY JOHN F - Director - Officer CHAIRMAN & CEO

2021-04-05 18:17:23 -0400 2021-04-01 S 7,500 $10.00 d 821,524 direct yes -1.9874 -2.6151 0.0 1 -3.8703 4

PROUT SAMANTHA - Officer PRINCIPAL ACCOUNTING OFFICER

2021-03-30 17:26:33 -0400 2021-03-26 F 435 $9.59 d 64,674 direct 1.8219 -6.1741 1.8219 2 -6.1741 6

CROWLEY JOHN F - Director - Officer CHAIRMAN & CEO

2021-03-24 17:11:56 -0400 2021-03-22 S 7,682 $10.29 d 829,024 direct yes 0.9474 5.8947 5.8947 6 -3.1579 3

CROWLEY JOHN F - Director - Officer CHAIRMAN & CEO

2021-03-17 19:11:17 -0400 2021-03-15 M 22,000 d 42,557 direct

CROWLEY JOHN F - Director - Officer CHAIRMAN & CEO

2021-03-17 19:11:17 -0400 2021-03-15 S 22,000 $10.77 d 836,706 direct yes 0.8858 -6.4961 2.7559 3 -7.6772 5

CROWLEY JOHN F - Director - Officer CHAIRMAN & CEO

2021-03-17 19:11:17 -0400 2021-03-15 M 22,000 $6.45 a 858,706 direct 0.8858 -6.4961 2.7559 3 -7.6772 5

QUIMI DAPHNE - Officer CHIEF FINANCIAL OFFICER

2021-03-09 17:38:33 -0500 2021-03-05 M 16,628 d 0 direct

QUIMI DAPHNE - Officer CHIEF FINANCIAL OFFICER

2021-03-09 17:38:33 -0500 2021-03-05 F 4,664 $10.48 d 271,334 direct 3.8499 1.4437 3.9461 4 0.0 1

QUIMI DAPHNE - Officer CHIEF FINANCIAL OFFICER

2021-03-09 17:38:33 -0500 2021-03-05 M 16,628 $2.94 a 275,998 direct 3.8499 1.4437 3.9461 4 0.0 1

CAMPBELL BRADLEY L - Director - Officer CHIEF OPERATING OFFICER

2021-03-03 19:03:19 -0500 2021-03-01 M 10,514 d 27,651 direct

CROWLEY JOHN F - Director - Officer CHAIRMAN & CEO

2021-03-03 19:04:09 -0500 2021-03-01 S 7,500 $11.85 d 836,706 direct yes 1.256 4.2512 -3.9614 4.3478 8 -11.2077 26

CAMPBELL BRADLEY L - Director - Officer CHIEF OPERATING OFFICER

2021-03-03 19:03:19 -0500 2021-03-01 S 10,514 $11.84 d 378,857 direct yes 1.256 4.2512 -3.9614 4.3478 8 -11.2077 26

WHITMAN BURKE W - Director

2021-03-03 18:58:46 -0500 2021-03-01 P 1,500 $12.40 a 42,967 direct yes 1.256 4.2512 -3.9614 4.3478 8 -11.2077 26

CAMPBELL BRADLEY L - Director - Officer CHIEF OPERATING OFFICER

2021-03-03 19:03:19 -0500 2021-03-01 M 10,514 $6.45 a 389,371 direct 1.256 4.2512 -3.9614 4.3478 8 -11.2077 26

CROWLEY JOHN F - Director - Officer CHAIRMAN & CEO

2021-02-24 17:07:50 -0500 2021-02-22 S 7,682 $11.98 d 844,206 direct yes 3.0201 -13.1711 -22.9027 3.0201 2 -22.9027 31

CROWLEY JOHN F - Director - Officer CHAIRMAN & CEO

2021-02-18 18:48:48 -0500 2021-02-16 M 22,000 $6.45 a 873,888 direct -2.9869 0.491 -18.6579 0.491 6 -24.7136 27

CROWLEY JOHN F - Director - Officer CHAIRMAN & CEO

2021-02-18 18:48:48 -0500 2021-02-16 M 22,000 d 64,557 direct

CROWLEY JOHN F - Director - Officer CHAIRMAN & CEO

2021-02-18 18:48:48 -0500 2021-02-16 S 22,000 $12.26 d 851,888 direct yes -2.9869 0.491 -18.6579 0.491 6 -24.7136 27

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
AMICUS THERAPEUTICS INC FOLD 2021-04-16 22:15:03 UTC -0.2191 0.2791 2100000
AMICUS THERAPEUTICS INC FOLD 2021-04-16 21:45:03 UTC -0.2191 0.2791 2100000
AMICUS THERAPEUTICS INC FOLD 2021-04-16 21:15:02 UTC -0.2191 0.2791 2100000
AMICUS THERAPEUTICS INC FOLD 2021-04-16 20:45:03 UTC -0.2624 0.3224 2100000
AMICUS THERAPEUTICS INC FOLD 2021-04-16 20:15:04 UTC -0.2624 0.3224 2100000
AMICUS THERAPEUTICS INC FOLD 2021-04-16 19:45:03 UTC -0.2624 0.3224 2100000
AMICUS THERAPEUTICS INC FOLD 2021-04-16 19:15:03 UTC -0.2624 0.3224 2100000
AMICUS THERAPEUTICS INC FOLD 2021-04-16 18:45:03 UTC -0.2624 0.3224 2100000
AMICUS THERAPEUTICS INC FOLD 2021-04-16 18:15:03 UTC -0.2624 0.3224 2100000
AMICUS THERAPEUTICS INC FOLD 2021-04-16 17:45:03 UTC -0.2624 0.3224 2100000
AMICUS THERAPEUTICS INC FOLD 2021-04-16 17:15:03 UTC -0.2624 0.3224 2100000
AMICUS THERAPEUTICS INC FOLD 2021-04-16 16:45:02 UTC -0.19 0.25 2100000
AMICUS THERAPEUTICS INC FOLD 2021-04-16 16:15:03 UTC -0.19 0.25 2100000
AMICUS THERAPEUTICS INC FOLD 2021-04-16 15:45:03 UTC -0.19 0.25 2100000
AMICUS THERAPEUTICS INC FOLD 2021-04-16 15:15:03 UTC -0.19 0.25 2100000
AMICUS THERAPEUTICS INC FOLD 2021-04-16 14:45:03 UTC -0.2091 0.2691 2100000
AMICUS THERAPEUTICS INC FOLD 2021-04-16 14:15:02 UTC -0.2091 0.2691 2100000
AMICUS THERAPEUTICS INC FOLD 2021-04-16 13:45:03 UTC -0.2091 0.2691 2100000
AMICUS THERAPEUTICS INC FOLD 2021-04-16 13:15:03 UTC -0.2091 0.2691 2100000
AMICUS THERAPEUTICS INC FOLD 2021-04-16 12:45:02 UTC -0.2091 0.2691 2100000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
FundVantage Trust- Gotham Hedged Plus Fund FOLD -2082.0 shares, $-48073.38 2020-12-31 N-PORT
FundVantage Trust- Gotham Defensive Long Fund FOLD -130.0 shares, $-1201.2 2020-03-31 N-PORT
FundVantage Trust- Gotham Master Neutral Fund FOLD -144.0 shares, $-2033.28 2020-09-30 N-PORT
VANGUARD MONTGOMERY FUNDS- VANGUARD MARKET NEUTRAL FUND FOLD -42442.0 shares, $-979985.78 2020-12-31 N-PORT

Elevate your investments